Welch Group LLC lowered its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 0.8% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 353,576 shares of the company’s stock after selling 2,908 shares during the quarter. Johnson & Johnson comprises approximately 3.2% of Welch Group LLC’s investment portfolio, making the stock its 5th biggest holding. Welch Group LLC’s holdings in Johnson & Johnson were worth $93,606,000 at the end of the most recent quarter.
A number of other hedge funds also recently made changes to their positions in the business. National Pension Service raised its stake in shares of Johnson & Johnson by 1.3% during the second quarter. National Pension Service now owns 5,226,968 shares of the company’s stock valued at $1,327,493,000 after purchasing an additional 67,484 shares in the last quarter. IFP Advisors Inc lifted its holdings in Johnson & Johnson by 8.8% in the second quarter. IFP Advisors Inc now owns 38,760 shares of the company’s stock worth $9,844,000 after purchasing an additional 3,133 shares during the period. Elefante Mark B grew its position in Johnson & Johnson by 9.8% in the 2nd quarter. Elefante Mark B now owns 28,686 shares of the company’s stock valued at $7,285,000 after buying an additional 2,563 shares in the last quarter. Gradient Investments LLC grew its position in Johnson & Johnson by 9.9% in the 2nd quarter. Gradient Investments LLC now owns 152,831 shares of the company’s stock valued at $38,815,000 after buying an additional 13,737 shares in the last quarter. Finally, AMG Asset Management Group Inc. increased its stake in Johnson & Johnson by 172.0% during the 3rd quarter. AMG Asset Management Group Inc. now owns 3,852 shares of the company’s stock valued at $1,020,000 after buying an additional 2,436 shares during the period. Institutional investors own 69.55% of the company’s stock.
Wall Street Analyst Weigh In
A number of research firms have commented on JNJ. Citigroup boosted their price target on shares of Johnson & Johnson from $298.00 to $303.00 and gave the stock a “buy” rating in a research report on Monday, October 5th. Argus set a $300.00 price objective on shares of Johnson & Johnson in a report on Wednesday, July 29th. Erste Group Bank lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Wednesday, October 21st. TD Cowen reissued a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, October 20th. Finally, UBS Group set a $270.00 target price on Johnson & Johnson in a research report on Wednesday, October 14th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus target price of $275.92.
Get Our Latest Analysis on Johnson & Johnson
Johnson & Johnson Trading Down 0.9%
Shares of JNJ stock opened at $270.81 on Tuesday. The stock has a 50-day simple moving average of $265.74 and a 200 day simple moving average of $247.22. The stock has a market capitalization of $651.93 billion, a P/E ratio of 41.03, a P/E/G ratio of 2.68 and a beta of 0.21. Johnson & Johnson has a fifty-two week low of $185.12 and a fifty-two week high of $282.02. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.53 by $0.06. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The firm had revenue of $25.40 billion for the quarter, compared to analysts’ expectations of $25.38 billion. During the same period in the previous year, the business earned $2.80 earnings per share. Johnson & Johnson’s revenue for the quarter was up 5.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, sell-side analysts expect that Johnson & Johnson will post 11.12 earnings per share for the current fiscal year.
Johnson & Johnson Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be paid a $1.34 dividend. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $5.36 annualized dividend and a dividend yield of 2.0%. Johnson & Johnson’s payout ratio is currently 81.21%.
Johnson & Johnson News Roundup
Here are the key news stories impacting Johnson & Johnson this week:
- Positive Sentiment: New real-world and observational analyses presented at the TCT 2026 symposium found lower in-hospital and short-term mortality among high-risk percutaneous coronary intervention patients supported by Impella pumps. The findings covered 1,379 patients in U.S. and European hospitals and compared favorably with results from the CHIP-BCIS3 study. Data Show Positive Survival and Patient Outcomes with Best-Practice Impella Support in HRPCI
- Positive Sentiment: A separate report cited a 94% success rate in a coronary-device trial, adding to evidence that Impella could improve outcomes in complex coronary procedures. Stronger clinical support could help J&J expand adoption of the devices and reinforce its medical-technology growth strategy. Johnson & Johnson reports 94% success rate in trial of coronary artery device
- Positive Sentiment: Clinicians also reviewed progress in the ongoing PROTECT IV trial, which is expected to provide additional evidence for Impella-supported high-risk procedures. Further positive results could improve confidence in the product’s long-term commercial potential. What Is Johnson & Johnson Signaling With Its New Impella Heart Pump Data?
- Neutral Sentiment: Exchange-traded funds purchased approximately $35.1 million of JNJ shares on October 29, suggesting institutional demand, though the transaction alone does not establish a lasting change in investor sentiment. ETFs Are Buying Johnson & Johnson
- Negative Sentiment: Some coverage questioned whether JNJ is fully valued after strong recent performance, including a reported 6.71% 30-day return and 31.76% year-to-date gain. That raises the risk that positive Impella news is already reflected in the stock and could limit near-term upside. Johnson & Johnson As Impella Data Fuels The Story, Is The Stock Fully Valued?
Insider Buying and Selling
In related news, EVP Jennifer Taubert sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $263.36, for a total value of $3,950,400.00. Following the sale, the executive vice president directly owned 194,451 shares in the company, valued at $51,210,615.36. The trade was a 7.16% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Elizabeth Forminard sold 15,918 shares of the stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the sale, the executive vice president directly owned 16,994 shares of the company’s stock, valued at approximately $4,367,458. This represents a 48.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 64,515 shares of company stock worth $17,271,766 in the last ninety days. 0.16% of the stock is currently owned by corporate insiders.
About Johnson & Johnson
Johnson & Johnson (NYSE: JNJ) is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.
Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.
Featured Stories
- Five stocks we like better than Johnson & Johnson
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AI—These 5 Stocks Are Getting Paid
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
